Please login to the form below

Not currently logged in
Email:
Password:

AVP-786

This page shows the latest AVP-786 news and features for those working in and with pharma, biotech and healthcare.

Otsuka presses on with Alzheimer’s agitation drug

Otsuka presses on with Alzheimer’s agitation drug

Despite these results, Otsuka has said it will continue the clinical development programme of AVP-786. ... According to the company, this decision is based on ‘insights derived from detailed analysis of data from the first and the second phase 3

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...